Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

5.8K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
5.8K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.5K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

4.4K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Increased 18F-FDG Avidity on PET/CT During Treatment for Rhabdomyosarcoma Confirmed to Be Mature Rhabdomyoblasts.

Journal of pediatric hematology/oncology·2026
Same author

Paediatric Therapeutic Development Workshop on rhabdomyosarcoma.

British journal of cancer·2026
Same author

NAPRT expression and epigenetic regulation in pediatric rhabdomyosarcoma as a potential biomarker for NAMPT inhibition.

Molecular cancer therapeutics·2026
Same author

Trabectedin and low-dose irinotecan to target EWS::FLI1 in Ewing sarcoma: a phase 1/2 trial.

Nature medicine·2026
Same author

Resection of a Deep Pubic Alveolar Rhabdomyosarcoma With an Inferior Pubic Ramus Osteotomy Through a Perineal Approach: A Case Report.

Case reports in orthopedics·2026
Same author

Biological Advances and Current Challenges for Pediatric Rhabdomyosarcoma.

Cancers·2026

Related Experiment Video

Updated: Nov 15, 2025

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

9.9K

Relapsed Rhabdomyosarcoma.

Christine M Heske1, Leo Mascarenhas2

  • 1Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.

Journal of Clinical Medicine
|March 6, 2021
PubMed
Summary

Relapsed rhabdomyosarcoma (RMS) is a challenge, with most patients relapsing within three years. Favorable prognosis patients may achieve cure with multiagent chemotherapy, while others require clinical trial enrollment.

Keywords:
chemotherapyclinical trialsprognosisrelapserhabdomyosarcomarisk-factors

More Related Videos

Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model
13:41

Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model

Published on: January 13, 2023

2.6K
Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas
09:21

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas

Published on: September 13, 2019

7.4K

Related Experiment Videos

Last Updated: Nov 15, 2025

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

9.9K
Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model
13:41

Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model

Published on: January 13, 2023

2.6K
Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas
09:21

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas

Published on: September 13, 2019

7.4K

Area of Science:

  • Pediatric Oncology
  • Cancer Recurrence
  • Sarcoma Research

Background:

  • Relapsed rhabdomyosarcoma (RMS) presents a significant therapeutic challenge.
  • Recurrence rates are high for both localized (nearly one-third) and metastatic (over two-thirds) RMS.
  • Prognosis post-relapse is influenced by various clinical and treatment factors.

Purpose of the Study:

  • To outline general principles for managing relapsed RMS.
  • To identify patient subgroups with favorable and unfavorable prognoses.
  • To guide treatment decisions for relapsed RMS patients.

Main Methods:

  • Review of clinical features impacting relapse likelihood and prognosis.
  • Analysis of initial treatment aspects and relapse characteristics.
  • Discussion of general principles for care approach.

Main Results:

  • Favorable prognosis factors include botryoid RMS or stage 1/group I embryonal RMS (ERMS) without prior cyclophosphamide.
  • Patients with favorable prognosis have better cure chances with multiagent chemotherapy.
  • Majority of patients have poor outcomes with standard regimens; clinical trials are recommended.

Conclusions:

  • A structured approach to relapsed RMS care is essential, including biopsy, prognostic assessment, and goal discussion.
  • Targeted chemotherapy can benefit select patients with favorable prognostic features.
  • Enrollment in clinical trials is crucial for the majority of relapsed RMS patients with poor prognoses.